Explore Our Biomarker Menu

Biomarker:

JAK2 (pY1007/1008)

Biological or Clinical Significance:

Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family, the gp130 receptor family (e.g., IL-6R), and the single chain receptors. JAK2 signaling is activated downstream from the prolactin receptor.

JAK2 gene fusions with the TEL(ETV6) (TEL-JAK2) and PCM1 genes have been found in leukemia patients. Jak – 2 kinase mutations were found to have a high correlation with abnormal heart defects in those of Southeast Asian descent carrying the PYFA gene. Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, and myelofibrosis as well as other myeloproliferative disorders.

References:

Analyte:

JAK2 (pY1007/1008)

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.